CureToday: UC enrolling patients for glioblastoma trial
A new clinical trial at the University of Cincinnati is studying the effectiveness of a new two-pronged immunotherapy treatment procedure to treat the most aggressive and deadly type of brain tumors, called glioblastomas. Originating from healthy brain cells, glioblastomas can form in any area of the brain.
Soma Sengupta, MD, PhD, said the trial will administer two immunotherapy drugs in tandem with each other. She noted previous research has shown a single-arm immunotherapy treatment has not been effective, leading to the combination therapy being tested in the trial.
In collaboration with the Dana-Farber Cancer Insitute in Boston, a teaching affiliate of Harvard Medical School, researchers aim to enroll 24 patients in the Phase 1 study.
For more trial and enrollment information, contact Alex Love at lovea4@ucmail.uc.edu.
Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.
Related Stories
UC named a best employer in Ohio by Forbes
August 14, 2026
Forbes ranks the University of Cincinnati No. 24 on its 2026 America’s Best Employers By State list for Ohio, recognizing UC’s strong workplace culture and employee experience.
Mistakes to avoid when shopping for a product dupe
August 13, 2026
The University of Cincinnati’s Kelly Dobos was featured in an AARP article discussing ways to determine if “dupe” cosmetic products really are comparable to the more expensive name brand.
Ancient warming event hints at potential climate tipping point
August 12, 2026
Researchers say a spike in temperatures during an ice age 304 million years ago could inform what climate scientists are learning about rapidly changing conditions today.